Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors
Keywords
-
Journal
Lancet Diabetes & Endocrinology
Volume 9, Issue 9, Pages 586-594
Publisher
Elsevier BV
Online
2021-07-22
DOI
10.1016/s2213-8587(21)00180-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City
- (2021) David M. Charytan et al. Kidney International Reports
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
- (2021) Hiddo J L Heerspink et al. EUROPEAN HEART JOURNAL
- Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
- (2021) Kamlesh Khunti et al. Lancet Diabetes & Endocrinology
- Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
- (2020) Husam Ghanim et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
- (2020) Giacomo Grasselli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiac troponins predict mortality in patients with COVID-19: A meta-analysis of adjusted risk estimates
- (2020) Mislav Vrsalovic et al. JOURNAL OF INFECTION
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis
- (2020) Raymond Pranata et al. POSTGRADUATE MEDICAL JOURNAL
- The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
- (2020) Ken Ohara et al. Diabetology & Metabolic Syndrome
- Factors associated with COVID-19-related death using OpenSAFELY
- (2020) Elizabeth J. Williamson et al. NATURE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Adjusted win ratio with stratification: Calculation methods and interpretation
- (2020) Samvel B Gasparyan et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Practical recommendations for the management of diabetes in patients with COVID-19
- (2020) Stefan R Bornstein et al. Lancet Diabetes & Endocrinology
- Empagliflozin suppresses inflammation and protects against acute septic renal injury
- (2020) Zaid H. Maayah et al. INFLAMMOPHARMACOLOGY
- COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up
- (2020) Amir Tajbakhsh et al. Expert Review of Anti-Infective Therapy
- High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis
- (2020) Camila Barbosa Oliveira et al. JOURNAL OF CLINICAL PATHOLOGY
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study
- (2020) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- (2018) Fabrice Bonnet et al. DIABETES & METABOLISM
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- A recycling framework for the construction of Bonferroni-based multiple tests
- (2009) C.-F. Burman et al. STATISTICS IN MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search